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Abstract
Background: To describe the clinical and microbiological data of carbapenem-resistant Enterobacteriaceae (CRE)
infections, the treatment used, hospital- and infection-related mortality, and risk factors for death.
Methods: A prospective cohort conducted from March 2011 to December 2012. Clinical, demographic, and
microbiological data such as in vitro sensitivity, clonality, carbapenemase gene mortality related to infection, and
overall mortality were evaluated. Data were analyzed using Epi Info version 7.0 (CDC, Atlanta, GA, USA) and SPSS
(Chicago, IL, USA).
Results: One hundred and twenty-seven patients were evaluated. Pneumonia, 52 (42 %), and urinary tract infections
(UTI), 51 (40.2 %), were the most frequent sites of infection. The isolates were polyclonal; the BlaKPC gene was found in
75.6 % of isolates, and 27 % of isolates were resistant to colistin. Mortality related to infection was 34.6 %, and was
higher among patients with pneumonia (61.4 %). Combination therapy was used in 98 (77.2 %), and monotherapy in
22.8 %; 96.5 % of them were UTI patients. Shock, age, and dialysis were independent risk factors for death. There was
no difference in infection-related death comparing colistin-susceptible and colistin-resistant infections (p = 0.46);
neither in survival rate comparing the use of combination therapy with two drugs or more than two drugs (p = 0.32).
Conclusions: CRE infection mortality was higher among patients with pneumonia. Infections caused by colistin-
resistant isolates did not increase mortality. The use of more than two drugs on combination therapy did not show a
protective effect on outcome. The isolates were polyclonal, and the blaKPC gene was the only carbapenemase found.
Shock, dialysis, and age over 60 years were independent risk factors for death.
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Background
Carbapenem-resistant Enterobacteriaceae (CRE), and in
particular, carbapenemase-producing KPC type have be-
come globally endemic [1–3]. CRE resistance to colistin
has been reported in several countries in the last years
[4–7] and infections caused by these bacteria are
associated with high mortality [8–10]. KPC is the most
frequent carbapenemase described in Enterobacteriaceae
in Brazil with great mortality [8, 11]. One cohort study
in Brazil described 118 patients with CRE infections in a
period of almost four years. The authors reported
catheter-related bloodstream infections as the most fre-
quent among these patients resulting in overall 30-day
mortality rate of 45 % [11].
Risk factors associated with death in CRE infections
are those related to the seriousness of patients’ conditions
and infections, such as the APACHE and SOFA scores,
systemic infections, and sepsis [4, 6, 8, 9]. Although,
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colistin resistance has been associated with high mortality,
there is controversy about the impact of resistance to co-
listin on prognosis [9, 10, 12–15]. Combination therapy
has been advocated as the treatment of choice to treat sys-
temic infection, mainly bloodstream infection caused by
CRE [12–15]; however, the impact of such strategy on treat-
ment of other types of infection, such as pneumonia and
urinary tract infection, and the benefit of combination ther-
apy with more than two drugs need to be better addressed.
Thus, the knowledge of risk factors for death in infec-
tions such as those caused by CRE could be useful in
directing therapeutic resources in high-risk patients and
planning intervention in preventable factors that can re-
duce mortality.
The objectives of this study were to describe the clinical
and microbiological characteristics of CRE infections, in-
cluding pneumonia susceptible and resistant to colistin,
the treatment regimens used, infection-related mortality,
and risk factors associated with death.
Methods
Study population and design
A prospective cohort was conducted at the 317-bed Uni-
versity Hospital of Londrina (Paraná, Brazil), from March
2011 to December 2012. This is a public university hos-
pital, with ten Intensive Care Units (ICU) beds, ten Burn
unit beds, that serving a geographic region with an esti-
mated population of 1,790,000 inhabitants. Adult patients
(≥18 years) with documented infection by CRE were ac-
companied. The Ethics Committee of the State University
of Londrina and the Medical School of the University of
São Paulo approved the study. All patients or their legal
representatives filled out a form agreeing to participate in
this study, which was approved (number 0318/12) by the
ethics committee of both hospitals.
Data collection and definitions
Data collection
Data were collected and analyzed from patient’s charts
and the electronic hospital database.
Case definition
Hospitalized patients treating infections in any site with
culture results showing CRE as etiologic agents.
Definition of infection
Healthcare-associated infections were diagnosed ac-
cording to Centers for Disease Control and Prevention
definitions [16]. Severity of infections and sepsis were
categorized as stated by the consensus meeting of the
American College of Chest Physicians/Society of Critical
Care Medicine criteria. Severe sepsis was defined as sepsis
that was associated with tissue hypoperfusion and organ
dysfunction that was depicted by oliguria, lactic acidosis,
altered level of consciousness and hypotension without a
need for vasopressors. Septic shock was indicated when
administering vasopressors was necessary as a result of
sepsis-induced hypoperfusion refractory to adequate fluid
resuscitation [17].
The following demographic data were collected: age,
gender, and the presence of comorbidities. Comorbidities
were defined according to Charlson’s criteria and patients
were categorized in four groups according to the number
of comorbidities present (0, 1, 2, or ≥ 3 comorbidities) [18].
 The clinical variables were: admission to the
intensive care unit (ICU), length of hospital and
ICU stay, dialysis, site of infection, samples for
culture (quantitative tracheal aspirate, blood, urine,
tissues, and fluids), presence of severe sepsis and
septic shock, co-infection by other pathogens, colistin
resistance, and death associated with infection. Only
the first sample was considered when the patient had
more than one infection. The adopted cut-off point
for positivity of quantitative tracheal aspirate was
105 CFU/mL. Only the antimicrobials initiated in the
first 72 h after diagnose of ECR infections and used
for more than 48 h were assessed. Initial therapy
was categorized as the following: monotherapy,
combination therapy, and the starting time (less
than 12 h; between 12 and 24 h; between 24 and
72 h; after 72 h). Antimicrobial therapy was considered
appropriate when given at least one in vitro sensitive
drug for a minimum of 48 h. The loading dose of
colistin and double dose of tigecycline were also
evaluated. Infection-related mortality was considered
when the cause of death was attributable to the
infection and the event occurred during the treatment.
Hospital mortality considered death from any cause
measured at hospital discharge.
Microbiology and molecular analysis
The bacteria were identified using the API 20E and API
20NE miniaturized method (6.0 version, bio-Mérieux,
Marcy L’Etoile, France).
Susceptibility testing
Minimum inhibitory concentrations (MICs) of colistin
(USP-Reference Standard Colistin Sulfate), imipenem,
meropenem, ertapenem, gentamicin, amikacin, tigecycline,
and meropenem (Astra Zeneca) against the clinical isolates
were determined using the broth microdilution method ac-
cording to the Clinical and Laboratory Standards Institute
(CLSI) protocol [19]. K. pneumoniae ATCC 13883 and
Escherichia coli ATCC 25922, obtained from the American
Type Culture Collection, were used as controls.
The MIC50 and MIC90 were determined and interpreted
as follows: colistin according to the European Committee
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on Antimicrobial Susceptibility Testing (EUCAST) [20],
tigecycline according to the Food and Drug Administration
(FDA), and for all the other microorganisms, CLSI criteria
was used [16].
Polymerase chain reaction
PCRs multiplex for genes encoding carbapenemases
(blaOXA-48-like; blaNDM; blaKPC) were performed in all
isolates as previously described by Bradford, Chen, and
Monteiro [21–23]. These three carbapenemases were
chosen to be analyzed because they are the most frequent
carbapenemases described in Brazil [23] and are among
the most common types described around the world.
Pulsed-field gel electrophoresis
PFGE was performed using Spe-I (Thermo Scientific,
Sinapse Biotecnologia Ltda) digestion of chromosomal
DNA Ultrapure Agarose (Invitrogen™, Life technologies)
Table 1 Univariate analysis of risk factors for infection-related death in 127 patients with infections caused by CRE
Characteristics Total (n = 127) Survivors (n = 83) Deaths (n = 44) RR (95 % CI) P
Patient related
Age (years) (SD) 55.7(18)
Age over 60 (%) 57(44.9) 32(38.5) 25(56.8) 1.29(0.99–1.70) 0.03
Male (%) 88(69.3) 59(71.0) 29(65.9) 0.91(0.68–1.22) 0.34
ICU (%) 98(77.2) 60(72.3) 38(86.4) 1.29(1.01–1.65) 0.054
Comorbidities (%) 97(76.4) 67(73.6) 30(83.3) 1.39(1.10–1.75) 0.01
=1 23(18.1) 19(22.9) 4(9,0) 0.74(0.58–0.94) 0.04
=2 32(25.2) 17(20.5) 15(34.0) 1.30(0.92–1.85) 0.07
3 or more 42(33.0) 22(26.5) 20(45.4) 1.37(0.99–1.88) 0.02
Surgery (%) 59(46.5) 41(49.4) 18(40.9) 0.88(0.69–1.14) 0.23
Dialyses (%) 45(35.4) 18(21.7) 27(61.4) 1.98(1.36–2.88) 0.0001
Previous colonization (%) 76(59.8) 50(60.2) 26(59.0) 0.98(0.75–1.27) 0.52
Infection (%)
Pneumonia 52(41.0) 25(30.1) 27(61.4) 1.60(1.18–2.18) 0.0006
UTI 51(40.2) 39(47.0) 12(27.3) 0.75(0.59–0.96) 0.02
Bloodstream 9(7.0) 7(8.4) 2(4.5) 0.82(0.56–1.20) 0.33
Tissue 13(10.2) 10(12.0) 3(6.8) 0.83(0.59–1.15) 0.27
Abdominal 2(1.6) 2(2.4) 0 0.64(0.56–0.73) 0.42
Sepsis 28(22.0) 27(32.5) 1(2.3) 0.58(0.48–0.70) 0.0001
Severe sepsis 21(16.5) 17(20.5) 4(9.0) 0.76(0.59–0.99) 0.07
Shock 63(49.6) 25(30.1) 38(86.4) 2.28(1.66–3.12) 0.0001
Infection site (%)
Lungs 46(36.2) 23(27.7) 23(52.7) 1.48(1.07–2.03) 0.005
Urine 51(40.2) 39(47.0) 12(27.3) 0.75(0.59–0.96) 0.02
Blood 21(16.5) 11(13.2) 10(22.7) 1.29(0.84–1.99) 0.13
Tissue 11 (8.7) 7(8.4) 4(9.1) 1.02(0.64–1.64) 0.56
Others 8(8.0) 8(9.6) 0 0.63(0.54–0.72) 0.02
Pathogen (%)
K. pneumoniae 113(89.0) 74(89.2) 39(88.6) 0.98(0.64–1.48) 0.57
Polymyxin-resistant 27(21.3) 17(20.5) 10(22.7) 1.04(0.75–1.44) 0.46
Polymicrobial 55(43.3) 34(41.0) 21(47.7) 1.10(0.84–1.42) 0.29
Co-infection A. baumannii 36(28.3) 22(26.5) 14(31.8) 1.09(0.81–1.47) 0.33
Co-infection P. aeruginosa 13(10.2) 7(8.4) 6 (13.6) 1.23(0.73–2.08) 0.26
blaKPC+ 96(75.6) 68(81.9) 28(63.6) 0.68(0.46–1.00) 0.02
CRE carbapenem-resistant Enterobacteriaceae, RR relative risk, CI confidence interval, SD Standard deviation, LOS length of stay, IQR interquartile range, UTI urinary
tract infection
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[24]. Restriction fragments were obtained by separation
using a CHEF DR®III system (Bio-Rad, Hercules, Calif.,
USA). Patterns were interpreted using BioNumerics®
version 7.1 (Applied Maths).
Statistical analysis
A database was built using the Epi Info 7.1.5.2 program.
A descriptive analysis was made of patient characteris-
tics. Continuous variables were expressed as mean and
standard deviation (SD), median and interquartile range
(ITQ), and compared by Wilcoxon’s test; the categorical
variables by Chi-squared and Fisher’s Exact tests. The
outcome studied was death related to infection. The
level of significance adopted for comparison of the vari-
ables in the bivariate test was the value of p < 0.05. A
multivariate analysis using multiple logistic regression
was performed to evaluate potential factors associated
with death related to infection. Two cohorts were analyzed
with the logistic regression, firstly all CRE infections were
included in the first model and secondly CRE infections
excluding UTIs were analyzed in the second model. Results
are expressed as relative risk (RR) and 95 % confidence
interval (CI). The variables with p < 0.10 in the bivariate
analysis and biological plausibility were tested in the multi-
variate analysis by forward stepwise using two models, one
with all infections and another excluding UTI infections.
Results
During the study period, 127 patients developed infec-
tions caused by CRE, all healthcare-associated infections.
The mean age was 55.7 (±18.0) years, 44.9 % aged above
60 years, and 88 (69.3 %) were male. One hundred and
thirteen (89.0 %) isolates were Klebsiella pneumoniae
and 8 were Enterobacter spp. Others pathogens found
were 3 Escherichia coli, 1 Citrobacter, 1 Serratia and 1
Providencia spp. Fifty-five infections (43.3 %) were poly-
microbial, and 36 (28.3 %) patients were co-infected with
Acinetobacter baumannii (Table 1). All causes mortality
at hospital discharge was 61.4 %. Infection-related mortal-
ity was 34.6 % and 30-day mortality was 28.3 % (Table 2).
Pneumonia and urinary tract infections were the most
frequent sites of infection, with 52 (42 %) and 51 (40.2 %)
cases, respectively. Most infections (77.2 %) occurred in
patients in the ICU, and in this group, the mean APACHE
II score was 20.6 (SD: 7.1), median SOFA at admission
was 7.5 (IQR: 5-11), and median SOFA at discharge was
7.1 (IQR: 2.5-12). All patients with pneumonia were on
mechanical ventilation. Median length of stay in the ICU
was 18 (IQR: 8-28.5) days. Regarding the severity of the
infection, 22.0 %, 16.5 %, and 49.6 % had sepsis, severe
sepsis, and septic shock, respectively.
Comorbidities were present in 76.4 % of the cases, and
the presence of three or more comorbidities was a risk
factor for death in the bivariate analysis (RR: 1:37; 95 %
Table 2 Comparison of mortality rates among 127 patients
infected by carbapenem-resistant Enterobacteriaceae in the ICU
and in the ward
Mortality Overall
(n = 127)
ICU (n = 98) Ward (n = 29) P
Hospital 78(61.4 %) 69(70.4 %) 9(31.0 %) <0.001
Infection-related 44(34.6 %) 38(38.8 %) 6(20.7 %) 0.05
30 days 36(28.3 %) 30(30.6 %) 6(20.7 %) 0.21
ICU intensive care unit
Fig. 1 Kaplan Meier survival curve comparing combination therapy with two drugs or more than two drugs in the treatment of carbapenem-resistant
infections, except urinary tract infections. Log rank test
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CI: 0.99-1.88; p = 0.02). Fifty-nine (46.5 %) patients under-
went surgery, and 35.4 % were submitted to dialysis. Dialy-
sis (RR: 1.98; 95 % CI: 1.36-2.88; p <0.0001), pneumonia
(RR 1.60, 95 % CI: 1.18-2.18; p <0.001), and shock (RR
2.28, 95 % CI: 1.66-3.12; p = <0.001) were risk factors for
infection-related death, and UTI was a protective factor
(RR 0.75, 95 % CI: 0.59-0.96; p = 0.02). The BlaKPC gene
was found in 75.6 %. Resistance to colistin occurred in
21.3 %, with no significant difference between deaths
related or not to infection (20.5 % and 22.7 %, respectively,
p = 0.46) (Table 1).
Monotherapy was used in 29 patients (22.8 %), 28
(96.5 %) had UTI, and combination therapy comprising
two, three, or more drugs was given to 98 (77.2 %) pa-
tients. Considering all infections except UTI, the use of
two, three, or more drugs was not associated with differ-
ences in mortality, according to Kaplan Meier’s survival
curve (Fig. 1). Twenty-seven patients had infection due
to colistin-resistant CRE (colistin MIC = 4 – 64 μg/mL).
The overall mortality in patients with UTI was 24 %; 6/
28(21 %) patients that received monotherapy died com-
pared with 6/23 (26 %) of patients that received combined
therapy (p = 0.47). There was no difference in infection-
related death comparing colistin-susceptible and colistin-
resistant UTI (p = 0.41). Among eight patients with UTI
caused by colistin-resistant CRE that received monotherapy,
only one patient with high colistin MIC = 16 μg/mL evolved
to death.
In the bivariate analysis, monotherapy was a protective
factor for death related to infection (RR: 0.77, 95 % CI:
0.60-0.98, p = 0.05); however, most of the patients re-
ceiving monotherapy had UTI (Table 3).
Sensitivity to colistin was observed in 78.7 % of the
cases, to tigecycline in 58.3 %, and to gentamicin in
18.1 %. Only Fosfomycin showed great sensitivity in
vitro (100 %), but its intravenous presentation is not
available in the country of the research and it was tested
in vitro only against polymyxin E-resistant strains
(Table 4).
In the first multivariate analysis including all CRE in-
fections, the presence of shock and dialysis remained as
predictors of death related to infection in the first model
(Table 5). In the second multivariate analysis, using a
model that excluded patients with UTI, the presence of
Table 3 Univariate analysis of therapeutic regimens used in patients with carbapenem-resistant infections on infection-related
deaths
Treatment Total (n = 127) N (%) Survivors (n = 83) N (%) Deaths (n = 44) N (%) RR (95 % CI) P
Less than12 h onset 39 (30.7) 20 (24.1) 19 (43.2) 1.39 (1.00–1.94) 0.02
12 h onset and sensitive 31 (24.4) 14 (16.9) 17 (38.6) 1.59 (1.05–2.39) 0.006
Less than 24 h onset 53 (41.7) 30 (36.1) 23 (52.3) 1.26 (0.96–1.66) 0.059
Monotherapy 29 (22.8) 23 (27.7) 6 (13.6) 0.77 (0.60–0.98) 0.054
Combined therapy 98 (77.2) 60 (72.3) 38 (86.4) 1.29 (1.01–1.65) 0.054
2 drugs 22 (17.3) 16 (19.3) 6 (13.6) 0.87 (0.65–1.17) 0.29
3 drugs 53 (41.7) 31 (37.3) 22 (50.0) 1.20 (0.91–1.57) 0.11
4 drugs 23 (18.1) 13 (15.6) 10 (22.7) 1.19 (0.81–1.74) 0.22
Colistin 107 (8.2) 67 (80.7) 40 (90.9) 1.27 (0.98–1.66) 0.10
Loading dose of colistin 74 (69.2) 43 (64.2) 31 (77.5) 1.25 (0.94–1.66) 0.10
Tigecycline 69 (54.3) 43 (51.8) 26 (59.0) 1.10 (0.86–1.42) 0.27
Double dose of tigecyclin 46 (66.8) 29 (67.5) 17 (65.4) 0.96 (0.65–1.43) 0.53
Carbapenem 69 (54.3) 42 (50.6) 27 (61.4) 1.16 (0.90–1.49) 0.16
Aminoglycoside 82 (64.6) 51 (61.4) 31 (70.4) 1.14 (0.88–1.47) 0.20
Use of more two or more
drugs with in vitro
activity on isolates
71 (55.9) 45 (54.2) 26 (59.0) 1.07 (0.83–1.37) 0.36
RR relative risk, CI confidence interval
Table 4 In vitro antibiotic sensitivity profile using microdilution
of 127 carbapenem-resistant enterobacteriaceae isolates
Antimicrobial Sensitive %(n) Tested
number
MIC to sensitivity Criteria
Polymyxin 78.7 (100) 127 ≤2ug/mL Eucast
Gentamicin 18.1 (23) 127 ≤4ug/mL CLSI
Tigecycline 58.3 (49) 84 ≤1ug/mL Eucast
92.8 (78) 84 ≤2ug/mL FDA
Fosfomycina 100.0 (29) 29 ≤64ug/mL CLSI
96.5 (28) 29 ≤32ug/mL Eucast
Imipenem 11.0 (14) 127 ≤1ug/mL CLSI
MIC minimum inhibitory concentration, Eucast European committee on
susceptibility testing, CLSI clinical and laboratory standards institute, FDA, food
and drug administration
aFosfomycin was tested only against polymyxin-resistant ERC
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shock, old age, and dialysis remained as independent risk
factors for death (Table 6). The dendrograms of 113K.
pneumoniae infections (Fig. 2) and 7 Enterobacter spp
infections (Fig. 2) showed that they were polyclonal. We
did not perform dendrogram of others pathogens be-
cause of number of isolates: 3 Escherichia coli, 1 Citro-
bacter spp., 1 Serratia spp. and 1 Providencia spp.
Discussion
The present study described a prospective cohort of hos-
pitalized adult patients with infection caused by CRE.
The blaKPC gene was the only one identified in the strains
studied. Monotherapy was used for UTI, and combination
therapy for other sites of infection. There was no differ-
ence in the Kaplan Meier survival curve comparing ther-
apy with two, three, or more drugs to treat systemic
infections. Age, dialysis, and presence of shock were inde-
pendent risk factors for infection-related death.
The high mortality of 34 % observed in this study was
similar to previous reports that showed mortality caused
by K. pneumoniae bacteremia harboring KPC ranging
from 39 to 82 % [2, 3, 9, 25]. In our study, 61.4 % of pa-
tients with pneumonia evolved to death; all patients
where on mechanical ventilation in the ICU. Some studies
have reported increased mortality among ICU patients
[6, 26]. Qureschi et al. [25] described that 10 of 41 patients
with pneumonia caused by K. pneumoniae harboring KPC
evolved for death. Capone et al. [12] reported a 42.9 %
mortality rate in patients with VAP caused by K. pneumo-
niae harboring KPC. More recently, Tumbarello et al. [27]
described a large cohort study describing lower 14-day
mortality among non-bacteremic patients (24,3 %) com-
paring to bacteremic (38,7 %). Among non-bacteremic pa-
tients, 85 patients had lower respiratory tract infections
with overall mortality of 40 %. Twenty-five percent of pa-
tients with lower respiratory tract infections that received
Table 5 Regression analysis of risk factors associated with infection-related death among 127 patients infected by CRE between
March 2011 and December 2012
Variable Total Survivors Deaths OR (95 % CI) P
First model
60 y or over 57 (44.9 %) 32 (38.5 %) 25 (56.8 %) 2.72
(0.93–7.95)
0.06
Shock 63 (49.6 %) 25 (30.1 %) 38 (86.4 %) 10.26
(2.95–35.68)
0.0002
Dialysis 45 (35.4 %) 18 (21.7 %) 27 (61.4 %) 2.94
(1.00–8.62)
0.04
Sensitive ATM less than 12 h 31 (24.4 %) 14 (16.9 %) 17 (38.6 %) 1.80
(0.63–5.14)
0.27
UTI 51 (40.2 %) 39 (47.0 %) 12 (27.3 %) 0.71
(0.14–3.62)
0.68
Pneumonia 52 (41.0 %) 25 (30.1 %) 27 (61.4 %) 1.58
(0.40–6.18)
0.50
Monotherapy 29 (22.8 %) 23 (27.7 %) 6 (13.6 %) 3.93
(0.71–21.53)
0.11
More than two comorbidities 42 (33.0 %) 22 (26.5 %) 20 (45.4 %) 1.27
(0.45–3.54)
0.64
CRE carbapenem-resistant infection, OR odds ratio, CI confidence interval, ATM antimicrobial
Table 6 Regression analysis models of risk factors associated with infection-related death among 76 patients infected by CRE, ex-
cluding urinary tract infections, between March 2011 and December 2012
Variable Total Survivors Deaths OR (95 % CI) P
First model
60 y or over 32 (42.1 %) 15 (34.0 %) 17 (53.1 %) 3.10 (0.81–11.87) 0.09
Shock 47 (61.8 %) 18 (38.3 %) 29 (61.7 %) 5.84 (1.30–26.12) 0.02
Dialysis 35 (46.0 %) 29 (61.7 %) 29 (61.7 %) 4.76 (1.22–18.55) 0.02
Sensitive ATM less than 12 h 25 (32.9 %) 11 (44.0 %) 14 (56.0 %) 1.51 (0.45–5.01) 0.49
Pneumonia 52 (68.4 %) 25 (48.0 %) 27 (56.0 %) 1.55 (0.40–6.03) 0.52
Monotherapy 1 (1.3 %) 1 (100 %) 0 (0 %) 0.0001 (0.00–0.00) 0.97
More than two comorbidities 1.50 (0.44–5.08) 0.50
CRE carbapenem-resistant infection, OR odds ratio, CI confidence interval, ATM antimicrobial
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Fig. 2 The dendrogram1 (113 K. pneumoniae infections) and dendrogram2 (7 Enterobacter spp) infections identified in the University Hospital of
Londrina (Paraná, Brazil), from March 2011 to December 2012. PFGE = Pulsed Field Gel Electrophoresis; PCR: Polymerase Chain Reaction; KPC;
Klebsiella pneumoniae carbapenemase
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combined therapy evolved for death comparing with 49 %
that received monotherapy (p = 0.03). Our patients had a
mortality higher than the non bacteremic patients de-
scribed by that author, but our study was composed
mainly by ICU patients, compared to only 29 % ICU ad-
missions by Tumbarello et al. [27].
In this study, bivariate analysis identified age, comorbid-
ities, pneumonia, dialysis, and presence of shock as signifi-
cant risk factors for mortality as well as the APACHE II
and SOFA scores at ICU discharge. In the regression ana-
lysis the independent risk factors were related to the ser-
iousness of patients’ conditions and age. Zarkotou et al.
[28] and Correa et al. [8] also described APACHE II and
age as risk factors for mortality and in the latter, dialysis
and use of vasoactive drugs remained as independent risk
factors in the multivariate analysis.
Several studies evaluated therapeutic regimens in
attempts to treat these infections. Capone et al. [12]
mentioned 23 different treatment regimens in a multi-
center prospective study with 97 patients. The evalu-
ation of multiple schemes is a complicating factor in
those analyzes. In our study between monotherapy
and combination therapy, we detected 16 different
treatment regimens. Some studies pointed towards mono-
therapy as responsible for higher mortality, especially in
systemic infections such as bacteremia [9, 15, 25]. In the
present study there was no record of monotherapy being
used to treat systemic infections, monotherapy was used
to treat localized UTI with good response. There was nei-
ther difference in mortality in patients who began appro-
priate therapy within 12 h of the infection diagnosis nor
benefit of using carbapenem in infections caused by CRE
presenting MIC < 4 ug/mL to treated pneumonia. These
findings differ from previous authors that demonstrated
that carbapenem combination therapy could be useful in
treating infections caused by low carbapenem MIC iso-
lates [29]. The Kaplan-Meier survival curve showed no
significant difference in mortality of systemic infections,
mainly pneumonia, caused by CRE treated with combina-
tions with two, three, or more drugs. These findings alert
to the importance of improving knowledge regarding the
use of combination therapy with more than two drugs to
treat CRE pneumonia and UTI, thus, this strategy can in-
crease costs and side effects. Several countries have de-
scribed the polyclonal spread of KPC-producing CRE [3],
similar to the findings of this study. Although, the study
was performed in a single center, the polyclonality allowed
us to show that our isolates demonstrated a high sensitiv-
ity to fosfomycin and tigecycline using FDA criteria, but
low sensitivity using EUCAST criteria. On the other, the
isolates showed high resistance to amikacin.
In the present study, the proportion of colistin-resistant
infections was similar to what was previous reported by
Zarkotou et al. [28] and Capone et al. [12], which
demonstrated 25 to 37 % of resistance to colistin. However,
unlike other studies, our data show no difference in mortal-
ity comparing patients infected by colistin-susceptible CRE
with those with infections caused by colistin-resistant iso-
lates. Among eight patients with UTI caused by colistin-
resistant CRE that received monotherapy, only one patient
with high colistin MIC = 16 μg/mL evolved to death. This
could perhaps be explained by the site of infection mainly
pneumonia and UTI. Previous authors have demonstrated
the success of monotherapy in treating UTI caused by CRE
[28, 30].
This study has limitations: it was conducted in a sin-
gle center and the number of combination therapies
used hinders the analysis of the benefit of a specific
combination.
Conclusion
CRE infections are polyclonal, have high overall and
infection-related mortality, and KPC was the only carba-
penemase identified in our isolates. Mortality was higher
among patients with pneumonia. There was no significant
difference in mortality comparing colistin-susceptible with
colistin-resistant infections. The Kaplan-Meier survival
curve showed no significant difference comparing com-
bination therapy with two, three, or more drugs to treat
systemic infections, mainly pneumonia. The independent
risk factors associated with death were age, dialysis, and
shock.
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